NCT04585477 2026-02-10Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)Stanford UniversityPhase 2 Recruiting80 enrolled
NCT00157209 2015-11-18Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)Merck KGaA, Darmstadt, GermanyPhase 2 Completed171 enrolled 12 charts
NCT00157196 2015-08-18Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III DiseaseMerck KGaA, Darmstadt, GermanyPhase 2 Completed22 enrolled 6 charts